3,545 Shares in Blueprint Medicines Co. (NASDAQ:BPMC) Purchased by Gotham Asset Management LLC

Gotham Asset Management LLC bought a new position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 3,545 shares of the biotechnology company's stock, valued at approximately $309,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BPMC. R Squared Ltd bought a new stake in shares of Blueprint Medicines during the 4th quarter worth $51,000. Headlands Technologies LLC acquired a new stake in Blueprint Medicines during the 4th quarter worth about $65,000. Thematics Asset Management purchased a new stake in Blueprint Medicines during the fourth quarter valued at about $72,000. Covestor Ltd lifted its stake in Blueprint Medicines by 62.7% during the fourth quarter. Covestor Ltd now owns 973 shares of the biotechnology company's stock valued at $85,000 after buying an additional 375 shares in the last quarter. Finally, Asset Management One Co. Ltd. acquired a new position in shares of Blueprint Medicines in the fourth quarter worth about $88,000.

Analyst Ratings Changes

Several equities research analysts recently commented on BPMC shares. JMP Securities restated a "market outperform" rating and issued a $125.00 price target on shares of Blueprint Medicines in a research report on Friday, February 14th. Wall Street Zen upgraded Blueprint Medicines from a "sell" rating to a "hold" rating in a report on Friday, May 2nd. Morgan Stanley started coverage on Blueprint Medicines in a report on Thursday, March 20th. They set an "equal weight" rating and a $100.00 price target on the stock. Wedbush reissued an "outperform" rating and set a $128.00 price target on shares of Blueprint Medicines in a research report on Thursday, May 1st. Finally, JPMorgan Chase & Co. raised their price objective on Blueprint Medicines from $126.00 to $129.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 4th. Five research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $126.56.

Blueprint Medicines Stock Up 1.2%

NASDAQ BPMC traded up $1.16 during trading on Friday, reaching $101.50. The company's stock had a trading volume of 353,347 shares, compared to its average volume of 781,410. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15. The stock has a market capitalization of $6.56 billion, a PE ratio of -93.98 and a beta of 0.83. Blueprint Medicines Co. has a 1-year low of $73.04 and a 1-year high of $121.90. The business has a 50-day moving average price of $90.77 and a 200-day moving average price of $94.63.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.32). The business had revenue of $149.41 million during the quarter, compared to analyst estimates of $158.31 million. Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. The firm's revenue for the quarter was up 55.5% on a year-over-year basis. During the same period in the previous year, the firm posted $1.40 EPS. On average, research analysts forecast that Blueprint Medicines Co. will post -1.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $101.75, for a total value of $231,379.50. Following the transaction, the chief operating officer now owns 66,992 shares of the company's stock, valued at $6,816,436. This trade represents a 3.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Ariel Hurley sold 3,203 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $92.62, for a total transaction of $296,661.86. Following the completion of the sale, the insider now owns 18,270 shares of the company's stock, valued at $1,692,167.40. The trade was a 14.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 12,777 shares of company stock valued at $1,256,490 over the last quarter. Insiders own 4.21% of the company's stock.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.